Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

Either Pioglitazone or Placebo Pioglitazone will be administered during this study in this Type 2 Diabetic population with Heart Failure to examine if there are any beneficial effects on diastolic and systolic function.

Myocardial blood flow (MBF) is measured using a PET scan, then participants will be randomized to pioglitazone or a placebo to examine the effects of the study drug on the effects on the systolic and diastolic function of the heart. In addition, myocardial insulin sensitivity change will be measured as well as myocardial fat content. The ratio of ATP: PCr will also be measured.

Inclusion criteria

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Male or female, aged 30-70 years
• Body Mass Index (BMI) of 27.5-40kg/m²
• HbA1c of 6.5 to 10%
• Blood pressure of less than or equal to 145/65mmHg
• eGFR greater than 45 ml/min/1.73m²
• Subject must have HFpEF (EF > 50% by ECHO screening)
• NYHA class II-III heart failure
• Only T2D patients treated with diet/exercise, metformin, sulfonylurea, metformin/SU, DPP4i or insulin will be studied.
• For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional [4 weeks] after the end of study participation.
• For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.

Exclusion criteria

• Subjects with history of osteoporosis or proliferative diabetic retinopathy
• Subjects with Heart failure due to restrictive or infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, severe valvular heart disease, etc. will be excluded
• Patients with symptomatic coronary artery disease.
• Subjects with significant change in diuretic management during the month prior to screening (defined by doubling of diuretic dose, or addition of another HF medication).
• Subjects treated with a GLP-1 RA or thiazolidinedione.
• Subjects treated with a SGLT2i
• Pregnancy or lactation
• Known allergic reactions to components of the study interventions.
• Any metal plates, parts, screws, shrapnel, pins in body, or cardiac (heart) pacemaker